Fulgent Genetics, Inc. FLGT Business Segments
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Revenue by Business | |||||
| Laboratory Services | $322.22M+13.7% | $283.47M-2.0% | $289.21M-53.3% | $618.97M-37.6% | |
| Therapeutic Development | $447K— | $0— | $0— | $0— | |
| Operating Income by Business | |||||
| Laboratory Services | -$7.51M— | —— | —— | $221.46M-67.2% | |
| Therapeutic Development | -$19.85M-19.8% | -$16.56M— | —— | -$816K— | |
| Cost Of Revenue by Business | |||||
| Laboratory Services | $184.96M+9.8% | $168.46M-3.7% | $175.01M-28.1% | $243.36M— | |
| Therapeutic Development | $5K— | $0— | $0— | $0— | |
| Interest Expense Nonoperating by Business | |||||
| Laboratory Services | $75K— | —— | $488K-51.8% | $1.01M— | |
| Therapeutic Development | $0— | $0— | $0— | $0— | |
| Finite Lived Intangible Assets Gross by Business | |||||
| Laboratory Services | $332.45M0.0% | $332.41M— | —— | —— | |
| Finite Lived Intangible Assets Net by Business | |||||
| Laboratory Services | $261.94M-10.8% | $293.7M— | —— | —— | |
| Selling And Marketing Expense by Business | |||||
| Laboratory Services | $40.35M+24.8% | $32.34M-11.4% | $36.5M+5.7% | $34.55M— | |
| Therapeutic Development | $5K— | $0— | $0— | $0— | |
| Total Assets by Business | |||||
| Laboratory Services | $4.41B-3.4% | $4.56B— | —— | —— | |
| Therapeutic Development | $425.85M+19.9% | $355.04M— | —— | —— | |
| Investment Income Interest by Business | |||||
| Laboratory Services | $30.92M-1.2% | $31.3M+44.8% | $21.61M+284% | $5.62M— | |
| Therapeutic Development | $0— | $0— | $0— | $0— | |
| Research And Development Expense by Business | |||||
| Laboratory Services | $21.64M+18.8% | $18.21M-7.0% | $19.58M+10.5% | $17.72M— | |
| Therapeutic Development | $19.04M+21.8% | $15.63M+124% | $6.99M+837% | $746K— | |
| General And Administrative Expense by Business | |||||
| Laboratory Services | $82.78M+19.3% | $69.37M-7.5% | $74.98M-26.4% | $101.89M— | |
| Therapeutic Development | $1.25M+34.5% | $928K+36.3% | $681K+873% | $70K— | |
| D&A by Business | |||||
| Laboratory Services | $23.55M-2.8% | $24.24M-4.8% | $25.45M-21.8% | $32.56M+196% | |
| Therapeutic Development | $571K-17.0% | $688K-0.3% | $690K+557% | $105K— | |
| Allocated Share Based Compensation Expense by Business | |||||
| Laboratory Services | $31.57M-14.6% | $36.95M+3.7% | $35.65M+9.2% | $32.64M— | |
| Therapeutic Development | $8.02M+6.4% | $7.53M+3.5% | $7.27M— | $0— | |
| Finite Lived Intangible Assets Accumulated Amortization by Business | |||||
| Laboratory Services | $92.68M+39.2% | $66.59M— | —— | —— | |
| Goodwill by Business | |||||
| Therapeutic Development | $94.36M+7.0% | $88.22M— | —— | —— | |
| Revenue by Geography | |||||
| Non Us | $26.12M+1.9% | $25.64M+26.7% | $20.24M+27.9% | $15.82M+16.3% | |
| Other Countries | $13.21M+1.6% | $13.01M+48.0% | $8.79M+27.7% | $6.88M— | |
| PP&E (Net) by Geography | |||||
| Non Us | $25.72M+23.7% | $20.79M— | —— | —— | |
| Other Countries | $6.8M— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Fulgent Genetics, Inc. break its business down?
- Fulgent Genetics, Inc. (FLGT) reports revenue by business across 2 parts — Laboratory Services and Therapeutic Development. Each is extracted from the segment footnotes and tracked over time.
- Where does Fulgent Genetics, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Fulgent Genetics, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
